A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)
A Phase III Randomized Controlled Clinical Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)
This trial is a registrational Phase III, randomized, open-label, multicenter study designed to compare the efficacy and safety of BL-B01D1 in combination with a PD-1 monoclonal antibody versus nab-paclitaxel in combination with a PD-1 monoclonal antibody in patients with PD-L1-positive, previously untreated, inoperable locally advanced or recurrent metastatic triple-negative breast cancer.
연구 개요
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Sa Xiao, PHD
- 전화번호: +8615013238943
- 이메일: xiaosa@baili-pharm.com
연구 장소
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, 중국
- 모병
- Fudan University Shanghai Cancer Center
-
연락하다:
- Jiong Wu
-
수석 연구원:
- Jian Zhang
-
수석 연구원:
- Jiong Wu
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Voluntarily sign the informed consent form and agree to comply with the protocol requirements;
- Female patients aged 18 to 75 years;
- Expected survival time ≥ 3 months;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- Pathologically confirmed recurrent or metastatic triple-negative breast cancer;
- Confirmed PD-L1 expression positivity by central laboratory testing;
- No prior systemic anti-tumor therapy in the advanced/recurrent or metastatic setting;
- Agree to provide archived tumor tissue specimens (surgical specimens) or fresh tissue samples from primary or metastatic lesions obtained within 3 years;
- Must have at least one measurable lesion as defined by RECIST v1.1;
- Toxicities from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;
- No severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥ 50%;
- Organ function levels must meet the protocol-specified requirements;
- Urine protein ≤ 1+ or < 1000 mg/24 h;
- For premenopausal women of childbearing potential, a pregnancy test (serum) must be performed within 7 days before starting treatment, and pregnancy must be ruled out; patients must not be lactating. All enrolled patients (regardless of sex) must use adequate barrier contraception throughout the entire treatment period and for 7 months after the end of treatment.
Exclusion Criteria:
- Received surgery, radical radiotherapy, or immunotherapy within 4 weeks before the first dose;
- Prior exposure to ADC drugs with topoisomerase I inhibitor payload;
- Prior treatment with other T-cell receptor-targeting agents (excluding PD-1/PD-L1);
- Use of immunomodulators within 14 days before the first study drug dose;
- History of severe cardiac or cerebrovascular disease;
- Receiving chronic systemic corticosteroids at >10 mg/day prednisone before the first dose;
- Active autoimmune or inflammatory disease;
- Any thrombotic event within 6 months before randomization;
- Prolonged QTc, complete left bundle branch block, or similar;
- Active malignancy diagnosed within 3 years before randomization;
- Hypertension uncontrolled by two antihypertensives;
- Poorly controlled diabetes/hyperglycemia;
- History of steroid-treated ILD/interstitial pneumonitis;
- Concurrent lung disease causing clinically significant respiratory impairment;
- Active CNS metastases;
- Severe infection within 4 weeks before randomization;
- Massive or symptomatic serosal effusion;
- Severe non-healing wound, ulcer, or fracture within 4 weeks before consent;
- Clinically significant bleeding or bleeding tendency within 4 weeks before consent;
- Inflammatory bowel disease, extensive bowel resection, immune enteritis, bowel obstruction, or chronic diarrhea;
- Allergy or contraindication to the study drug;
- History of autologous/allogeneic stem cell transplantation;
- HIV antibody positive, active HBV, or active HCV;
- History of severe neurological or psychiatric illness;
- Received or planning to receive live vaccine within 28 days before randomization;
- Other conditions rendering the patient unsuitable per investigator's judgment.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: BL-B01D1+PD-1 monoclonal antibody
Participants receive BL-B01D1+PD-1 monoclonal antibody in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons. |
Administration by intravenous infusion for a cycle of 3 weeks.
다른 이름들:
Administration by intravenous infusion for a cycle of 3 weeks. |
|
활성 비교기: nab-paclitaxel+PD-1 monoclonal antibody
Participants receive nab-paclitaxel+PD-1 monoclonal antibody in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons. |
Administration by intravenous infusion for a cycle of 3 weeks. Administration by intravenous infusion for a cycle of 3 weeks. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
BICR-assessed Progression-free Survival (PFS)
기간: Up to approximately 24 months
|
Progression-free survival (PFS) as assessed by BICR is defined as the time between the date subjects were randomized and the first observation of disease progression (based on BICR's image-based assessment) or death. |
Up to approximately 24 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall Survival (OS)
기간: Up to approximately 24 months
|
Overall survival (OS) is defined as the time between the day the subject is randomized and the subject's death. |
Up to approximately 24 months
|
|
Investigator-assessed Progression-free Survival (PFS)
기간: Up to approximately 24 months
|
Investigator-assessed progression-free survival (PFS) per RECIST v1.1 is defined as the time from treatment initiation until the first documented disease progression according to RECIST v1.1 criteria, or death from any cause, whichever occurs first, as determined by the local treating investigator. |
Up to approximately 24 months
|
|
Objective Response Rate (ORR)
기간: Up to approximately 24 months
|
Objective response rate (ORR) is defined as the number of CR and PR in the treatment and control groups divided by the number of that group in the full analysis set (FAS). |
Up to approximately 24 months
|
|
Disease Control Rate (DCR)
기간: Up to approximately 24 months
|
Disease Control Rate (DCR) : Percentage of all randomized subjects who rated the best overall response (BOR) as complete response (CR), partial response (PR), and disease stabilization (SD) according to RECIST 1.1 criteria. |
Up to approximately 24 months
|
|
Duration of Response (DOR)
기간: Up to approximately 24 months
|
Duration of Response (DOR) : defined as the period from the date when tumor response is first recorded to the date when objective tumor progression is first recorded or the date of death. |
Up to approximately 24 months
|
|
Time to Response (TTR)
기간: Up to approximately 24 months
|
Time to Response (TTR) is defined as the time from randomization to the first documented response (CR or PR) according to RECIST v1.1 criteria. |
Up to approximately 24 months
|
|
Treatment Emergent Adverse Event (TEAE)
기간: Up to approximately 24 months
|
TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-B01D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-B01D1. |
Up to approximately 24 months
|
|
Cmax
기간: Up to approximately 24 months
|
Maximum serum concentration (Cmax) of BL-B01D1 will be investigated. |
Up to approximately 24 months
|
|
Tmax
기간: Up to approximately 24 months
|
Time to maximum serum concentration (Tmax) of BL-B01D1 will be investigated. |
Up to approximately 24 months
|
|
T1/2
기간: Up to approximately 24 months
|
Half-life (T1/2) of BL-B01D1 will be investigated. |
Up to approximately 24 months
|
|
AUC0-t
기간: Up to approximately 24 months
|
AUC0-t is defined as area under the serum concentration-time curve from time 0 to the time of the last measurable concentration. |
Up to approximately 24 months
|
|
CL (Clearance)
기간: Up to approximately 24 months
|
CL in the serum of BL-B01D1 per unit of time will be investigated. |
Up to approximately 24 months
|
|
Ctrough
기간: Up to approximately 24 months
|
Ctrough is defined as the lowest serum concentration of BL-B01D1 prior to the next dose will be administered. |
Up to approximately 24 months
|
|
Anti-drug Antibody (ADA)
기간: Up to approximately 24 months
|
Frequency of anti-BL-B01D1 antibody (ADA) will be investigated. |
Up to approximately 24 months
|
|
Neutralizing Antibody(NAb)
기간: Up to approximately 24 months
|
Frequency of anti-BL-B01D1 neutralizing antibodies will be investigated. |
Up to approximately 24 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- BL-B01D1-325
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .